Clinical trials / NCT07001800
NCT07001800Phase 2, phase 3Recruiting

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Study sponsor: Kardigan, Inc. · KARD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2028-08-31Estimated
Enrollment · participants1276Estimated
Source updated2026-07-06Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48

+ After

Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48

Planned enrollment decreased by 134 participants

− Before

1410 participants (planned)

+ After

1276 participants (planned)

Phase changed

− Before

PHASE3

+ After

PHASE2, PHASE3

Check registry source